Estimates suggest that brain tumors are underreported in the Alberta Cancer Registry (ACR). While the reporting of malignant tumors is thought to be complete in cancer registries across Canada, the reporting of benign tumors is estimated at 33 percent of the actual number of cases expected within the country.6 There are many international studies that highlight the issues of underreporting of benign brain tumors in cancer registries. This study had 3 objectives to investigate the amount of and potential reasons for underreporting: 1) overall case ascertainment of pediatric brain tumor cases present in physician databases captured by the ACR was assessed; 2) overall case ascertainment of all known pediatric brain tumors was assessed and summarized for the ACR and physician pediatric brain tumor databases; and 3) the expected number of unknown pediatric brain tumor cases was estimated so overall case ascertainment could be assessed. Brain cancer was defined using topography codes C70 through C72, C75.1 through C75.3, and C30.0 (with morphology codes 9522 and 9523). Databases with these codes from 2 physician practices making up the primary provincial referral network for this patient population were obtained and linked with the ACR for 2004 to 2011. Estimates of the expected number of cases were made using US incidence rates. The ACR captured 309 of the 317 known pediatric brain tumor cases (97 percent) while the physician databases captured 205 cases (65 percent). The ACR also captured 197 of the 205 cases in the physician databases (96 percent). The ACR captured 309 of the 346 expected cases (89 percent) while the physician databases captured 205 of the 346 expected cases (59 percent). As some patients may not have an initial diagnosis confirmed (by specialty physicians) and others are identified through cause of death searches some discrepancies between the databases are expected. The overall underreporting may reflect a lack of referrals from radiology clinics or the case definition used by registries may not be consistent with the definition used by clinicians in Alberta. While further work is required to better understand why some cases are not appearing in the ACR, confidence should exist that ACR information reflects most cases of pediatric brain tumors in Alberta.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pediatric brain
28
case ascertainment
16
brain tumors
16
brain tumor
16
physician databases
16
cases percent
16
ascertainment pediatric
12
tumor cases
12
databases captured
12
acr captured
12

Similar Publications

Sleep Disturbance and Postconcussive Symptoms in Pediatric Mild Traumatic Brain Injury and Orthopedic Injury.

J Head Trauma Rehabil

September 2024

Author Affiliations: Department of Psychology, University of Calgary, Calgary, Alberta (Ms Luszawski and Dr Yeates); Alberta Children's Hospital Research Institute, Calgary, Alberta (Ms Luszawski and Dr Yeates); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta (Ms Luszawski and Dr Yeates); Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio (Ms Minich, Dr Bacevice, and Dr Bangert); Rainbow Babies and Children's Hospital, University Hospitals Cleveland Medical Center, Cleveland, Ohio (Ms Minich and Dr Bacevice); Department of Psychology and Neuroscience, Brigham Young University, Provo, Utah and Departments of Neurology and Psychiatry, University of Utah, Salt Lake City, Utah (Dr Bigler); Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio (Dr Taylor); Department of Pediatrics, The Ohio State University, Columbus, Ohio (Drs Taylor, Cohen, and Zumberge); Emergency Medicine, Nationwide Children's Hospital, Columbus, Ohio (Dr Cohen); Department of Radiology, University Hospitals of Cleveland, Cleveland, Ohio (Dr Bangert); Radiology, Nationwide Children's Hospital, Columbus, Ohio (Dr Zumberge); Educational and Counselling Psychology, University of British Columbia, Vancouver, British Columbia (Dr Tomfohr-Madsen); Neurosciences Program, Alberta Children's Hospital, Calgary, Alberta (Dr Brooks); and Departments of Pediatrics, Clinical Neurosciences, and Psychology, University of Calgary, Calgary, Alberta (Dr Brooks).

Objective: Sleep disturbance (SD) is common after pediatric mild traumatic brain injury (mTBI) and may predict increased postconcussive symptoms (PCS) and prolonged recovery. Our objective was to investigate the relation of SD with PCS in children with mTBI and those with orthopedic injury (OI).

Setting: Emergency departments (EDs) at 2 children's hospitals in the Midwestern United States.

View Article and Find Full Text PDF

Myotonic Dystrophy type 2 (DM2) is a multisystem disease affecting many tissues, including skeletal muscle, heart, and brain. DM2 is caused by unstable expansion of CCTG repeats in an intron 1 of a gene coding for cellular nuclear binding protein (CNBP). The expanded CCTG repeats cause DM2 pathology due to the accumulation of RNA CCUG repeats, which affect RNA processing in patients' cells.

View Article and Find Full Text PDF

Epileptic spasms (ES) are a unique seizure type typically presenting in the form of infantile epileptic spasms syndrome (IESS) with characteristic hypsarrhythmia on scalp EEG and a preponderance with developmental delay or regression. While pharmacotherapy is the mainstay of treatment, surgical options, including disconnective or resective procedures, are increasingly recognized as viable therapeutic options for recurrent or persistent ES. However, limited data on safety, effectiveness, and prognostic factors hinder informed decision-making regarding surgery indications, timing, and intervention type.

View Article and Find Full Text PDF

Objective: The study aims to investigate the long-term impacts of traumatic brain injury (TBI) on neuroinflammation and neuronal apoptosis in pediatric and adult mice, specifically focusing on how age-at-injury influences these processes.

Methods: Controlled cortical impact (CCI) was used to induce TBI in pediatric (21-25 days old) and adult (8-12 weeks old) C57Bl/6 male mice. Neuroinflammation was evaluated through immunoreactivity for Iba-1 and GFAP, while apoptosis was assessed using markers such as Bax, Bcl- 2, and pro-caspase-3.

View Article and Find Full Text PDF

Mannose Promotes β-Amyloid Pathology by Regulating BACE1 Glycosylation in Alzheimer's Disease.

Adv Sci (Weinh)

January 2025

Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiangan South Road, Xiamen, Fujian, 361102, P. R. China.

Hyperglycemia accelerates Alzheimer's disease (AD) progression, yet the role of monosaccharides remains unclear. Here, it is demonstrated that mannose, a hexose, closely correlates with the pathological characteristics of AD, as confirmed by measuring mannose levels in the brains and serum of AD mice, as well as in the serum of AD patients. AD mice are given mannose by intra-cerebroventricular injection (ICV) or in drinking water to investigate the effects of mannose on cognition and AD pathological progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!